Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Antihistamine OTC Switch Moves To Legal Arena After Committee Votes

Executive Summary

The potential OTC switch of the antihistamines Claritin, Allegra and Zyrtec will move into the legal arena following a review by FDA's Nonprescription and Pulmonary-Allergy Drugs Advisory Committees May 11.

You may also be interested in...



WellPoint Swears Off Switch Petitions; Antihistamine Campaign Had PR Costs

The adverse publicity surrounding WellPoint's petition to force an OTC switch of nonsedating antihistamines has convinced the insurer not to pursue similar efforts in the future, WellPoint Health Networks Chief Pharmacy Officer Robert Seidman told a recent IIR conference in Philadelphia

WellPoint Swears Off Switch Petitions; Antihistamine Campaign Had PR Costs

The adverse publicity surrounding WellPoint's petition to force an OTC switch of nonsedating antihistamines has convinced the insurer not to pursue similar efforts in the future, WellPoint Health Networks Chief Pharmacy Officer Robert Seidman told a recent IIR conference in Philadelphia

Zyrtec OTC Switch: Pfizer Says Rx Status Necessary For “Best Use” Of Drug

A forced OTC switch of Zyrtec would deprive consumers of the "health information component" doctors provide, which is needed for optimal care, Pfizer CEO Henry McKinnell said during the firm's April 24 annual meeting in Ann Arbor, Mich

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS037816

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel